MADISON, WI
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY INC, founded in 2021, is a community nonprofit in the Medical Research sector that reported $2.1M in total revenue in fiscal year 2024. Revenue surged 224% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.6M, a strong 80% operating margin.
THE ORGANIZATION'S PRIMARY EXEMPT PURPOSE IS TO ENGAGE IN THE CONTINUOUS ACTIVE CONDUCT OF MEDICAL RESEARCH IN CONJUNCTION WITH A HOSPITAL.
IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN...
IN 2024, WIICT CONTINUOUSLY CONDUCTED RESEARCH ON AND PROVIDED 4 DIFFERENT MRNAS TO ITS COLLABORATORS AT NIH CLINICAL CANCER CENTER IN BETHESDA, MD FOR EVALUATION AND USE IN CLINICAL RESEARCH AND IN DIFFERENT PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS. ONE OF THESE MRNAS ENCODES THE ACTIVE FORM OF A PROTEIN THAT IS INACTIVE OR LACKING IN ONE TYPE OF IMMUNE CELL OF PATIENTS HAVING A CERTAIN PRIMARY IMMUNODEFICIENCY (PID) DUE TO A MUTATION IN THE GENE THAT IS REQUIRED TO KILL MICROBIAL OR VIRAL PATHOGENS WITH WHICH THE PATIENT BECOMES INFECTED (ON AVERAGE EVERY 2-3 YRS). THIS TRIAL IS TESTING WHETHER PATIENTS CAN BE TREATED BY TRANSFECTING THE MRNA ENCODING THE ACTIVE PROTEIN INTO DEFECTIVE IMMUNE CELLS FROM THE PATIENT'S OWN BLOOD AND THEN REINTRODUCING THOSE TRANSFECTED CELLS INTO THE PATIENT. IN 2024, WIICT ALSO DESIGNED, MADE AND CONDUCTED RESEARCH ON THE YIELDS, PURITIES, ACTIVITIES, FUNCTIONS AND PROPERTIES OF MULTIPLE DIFFERENT BASE EDITING ENZYMES, GENE EDITING ENZYMES, AND BXB1 RECOMBINASE VARIANTS, WHICH MRNAS WERE PROVIDED TO OUR COLLABORATORS AND NIH, MASS GENERAL HOSPITAL AND ST JUDE'S CHILDREN'S HOSPITAL FOR THEIR EVALUATION AND RESEARCH RE ON- TARGET AND OFF-TARGET EDITING OF DIFFERENT GENES AND MUTATIONS IN HUMAN CELLS OR ANIMAL MODELS TO GENERATE DATA TO SUPPORT INDS FOR PHASE 1 OR PHASE 1/2 HUMAN CLINICAL TRIALS, INCLUDING BY USING DIFFERENT GUIDE RNAS AND OTHER CONDITIONS AND PARAMETERS TO ACHIEVE OPTIMAL EDITING OF SPECIFIC GENES AND MUTATIONS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $2,050,372 | $633,133 | +2.2% |
| Expenses | $404,954 | $711,144 | -0.4% |
| Net Income | $1,645,418 | $-78,011 | -22.1% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| GARY A DAHL | PRESIDENT | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| JEROME J JENDRISAK | VP, SEC/TREA | 1.00 |
Officer
Director
|
$0 | $0 | $0 |
| KIERAN COE | DIRECTOR | 0.10 |
Director
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $2,050,372 | $404,954 | $1,823,568 | $1,645,418 |
| 2023 | $633,133 | $711,144 | $192,955 | $-78,011 |
| 2022 | $500,000 | $292,215 | $265,501 | $207,785 |
Compare WISCONSIN INSTITUTE FOR IMMUNE AND CELL THERAPY INC with other nonprofits in Wisconsin and across the country.